These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 27440839)

  • 21. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.
    Blonde L
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Citrus unshiu peel extract ameliorates hyperglycemia and hepatic steatosis by altering inflammation and hepatic glucose- and lipid-regulating enzymes in db/db mice.
    Park HJ; Jung UJ; Cho SJ; Jung HK; Shim S; Choi MS
    J Nutr Biochem; 2013 Feb; 24(2):419-27. PubMed ID: 22694954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rosiglitazone: potential beneficial impact on cardiovascular disease.
    Viberti GC
    Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.
    Anagnostis P; Athyros VG; Adamidou F; Panagiotou A; Kita M; Karagiannis A; Mikhailidis DP
    Diabetes Obes Metab; 2011 Apr; 13(4):302-12. PubMed ID: 21205117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dangerous blood glucose peaks. Vascular damage even before diabetes].
    MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584214
    [No Abstract]   [Full Text] [Related]  

  • 27. Aspirin and Diabetes Mellitus: revisiting an old player.
    Manrique C; Lastra G; Palmer J; Gardner M; Sowers JR
    Ther Adv Cardiovasc Dis; 2008 Feb; 2(1):37-42. PubMed ID: 19124406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dangerous postprandial glucose peaks. Risk for heart and blood vessels].
    MMW Fortschr Med; 2002 May; 144(21):58. PubMed ID: 12134432
    [No Abstract]   [Full Text] [Related]  

  • 29. Aspirin response and failure in diabetic patients with cardiovascular disease.
    Yan Y; Phillips DR
    Curr Opin Pharmacol; 2005 Apr; 5(2):190-7. PubMed ID: 15780830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.
    Spallarossa P; Barsotti A; Cordera R; Ghigliotti G; Maggi D; Brunelli C
    J Endocrinol Invest; 2004 May; 27(5):485-95. PubMed ID: 15279085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
    Cariou B
    Diabetes Metab; 2012 Oct; 38(4):298-308. PubMed ID: 22672960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential Effects of Nonsteroidal Anti-Inflammatory Drugs in the Prevention and Treatment of Type 2 Diabetes Mellitus.
    Bellucci PN; González Bagnes MF; Di Girolamo G; González CD
    J Pharm Pract; 2017 Oct; 30(5):549-556. PubMed ID: 27194069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
    Marwick TH; Narula J
    JACC Cardiovasc Imaging; 2011 Oct; 4(10):1146-7. PubMed ID: 21999880
    [No Abstract]   [Full Text] [Related]  

  • 34. Multiple benefits of targeting inflammation in the treatment of type 2 diabetes.
    Donath MY
    Diabetologia; 2016 Apr; 59(4):679-82. PubMed ID: 26868493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes medications and cardiovascular disease: at long last progress.
    Lupsa BC; Inzucchi SE
    Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):87-93. PubMed ID: 29369916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control.
    Sarafidis PA; Bakris GL
    QJM; 2006 Jul; 99(7):431-6. PubMed ID: 16766516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
    Zimmet P; Collier G
    Drugs; 1999; 58 Suppl 1():21-8; discussion 75-82. PubMed ID: 10576521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of the anti-inflammatory effects of safranal on high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model.
    Hazman Ö; Ovalı S
    Inflammation; 2015; 38(3):1012-9. PubMed ID: 25411096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correction.
    Evid Based Med; 2015 Aug; 20(4):123. PubMed ID: 26209722
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.